aTyr Pharma, Inc.
Financials
Valuation Metrics
aTyr Pharma, Inc.'s Market Cap is $36M. At end of 2025 it was $77M. Ranked #3109 of 3,121 in US market (top 100%), #1452 of 1,463 on NASDAQ (top 99%), #266 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $36M | US#3,109/3,121 Sec#266/266 |
| Revenue | $190000.00 | US#2,884/3,121 Sec#193/266 |
| Net Income | $-61M | US—/3,121 Sec—/266 |
| Total Assets | $70M | US#3,074/3,121 Sec#265/266 |
| Net Assets | $49M | US#2,867/3,121 Sec#224/266 |
| Employees | 58 | US#2,704/3,121 Sec#208/266 |
| Value | ||
| P/B | 0.74x | US#192/3,121 Sec#4/266 |
| P/S | 190.06x | US#2,960/3,121 Sec#186/266 |
| FCF Yield | -151.80% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -124.64% | US#2,812/3,121 Sec#207/266 |
| ROA | -87.08% | US#3,052/3,121 Sec#250/266 |
| Op. Margin | -33609.47% | US#2,882/3,121 Sec#192/266 |
| Financial Health | ||
| Debt Ratio | 43.52% | US#492/3,121 Sec#135/266 |
| Total Debt | $11M | US#2,825/3,121 Sec#197/266 |
| FCF | $-55M | US#2,534/3,121 Sec#116/266 |
| Cash | $16M | US#2,905/3,121 Sec#262/266 |
| Current Ratio | 5.12x | US#460/3,121 Sec#142/266 |
| Performance | ||
| 1Y Return | -64.92% | US#3,033/3,121 Sec#253/266 |
| 1M Return | -30.87% | US#3,046/3,121 Sec#254/266 |
| From 52W High | -94.33% | US#3,123/3,121 Sec#268/266 |
| 1Y MDD | -93.89% | US#3,123/3,121 Sec#267/266 |
| Trading | ||
| Volume | 1,132,417 shares | US#1,395/3,121 Sec#151/266 |
| Trading Value | $421372.00 | US#3,085/3,121 Sec#263/266 |
| Per Share | ||
| EPS | $-0.62 | US—/3,121 Sec—/266 |
| BPS | $0.50 | US#2,756/3,121 Sec#221/266 |
Company Info
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.